ELIOT HOWARD OHLSTEIN
Pharmacy in Glenmoore, PA
License number
Pennsylvania RP033893R
Category
Pharmacy
Type
Pharmacist
Address
Address
Glenmoore, PA 19343
Professional information
Method Of Treating Isolated Systolic Hypertension
US Patent:
2003004, Mar 6, 2003
Filed:
Sep 19, 2002
Appl. No.:
10/247035
Inventors:
David Brooks - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
A61K031/4178
US Classification:
514/397000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.
Method Of Treating Isolated Systolic Hypertension
US Patent:
2001000, Jun 28, 2001
Filed:
Feb 6, 2001
Appl. No.:
09/777371
Inventors:
David Brooks - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
A61K031/47
US Classification:
514/310000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.
Method Of Treating Isolated Systolic Hypertension
US Patent:
2005011, May 26, 2005
Filed:
Dec 14, 2004
Appl. No.:
11/012041
Inventors:
David Brooks - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
International Classification:
A61K031/4184
US Classification:
514381000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.
Method Of Treating Isolated Systolic Hypertension
US Patent:
2007012, Jun 7, 2007
Filed:
Feb 12, 2007
Appl. No.:
11/673605
Inventors:
David BROOKS - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
International Classification:
A61K 31/4178
US Classification:
514397000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.
Treatment Of Athereosclerosis Using, Carbazolyl-(4)-Oxypropanolamine Compounds
US Patent:
5453436, Sep 26, 1995
Filed:
Mar 17, 1994
Appl. No.:
8/197645
Inventors:
Eliot H. Ohlstein - Glenmoore PA
Assignee:
Boehringer Mannheim Pharmaceutical Corporation - Rockville MD
SmithKline Beecham Corp. - Rockville MD
SmithKline Beecham Corp. - Rockville MD
International Classification:
A61K 3140
US Classification:
514411
Abstract:
A new use of, and method of treatment of atherosclerosis using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R. sub. 1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;
R. sub. 2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;
R. sub. 3 is hydrogen or lower alkyl of up to 6 carbon atoms;
R. sub. 4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R. sub. 4 together with R. sub. 5 can represent --CH. sub. 2 --O--;
X is a valency bond, --CH. sub. 2, oxygen or sulfur;
Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;
R. sub. 5 and R. sub. 6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH. sub. 2 -- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or
R. sub. 5 and R. sub.
Use Of, And Method Of Treatment Using, Carbazolyl-(4)-Oxypropanolamine Compounds For Inhibition Of Smooth Muscle Cell Proliferation
US Patent:
5643939, Jul 1, 1997
Filed:
Feb 16, 1994
Appl. No.:
8/197625
Inventors:
Eliot H. Ohlstein - Glenmoore PA
Assignee:
Boehringer Mannheim Pharmaceutical Corporation-SmithKline Beecham
Corporation - Gaithersburg MD
Corporation - Gaithersburg MD
International Classification:
A61K 3140
US Classification:
514411
Abstract:
A new use of, and method of treatment using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R. sub. 1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;
R. sub. 2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;
R. sub. 3 is hydrogen or lower alkyl of up to 6 carbon atoms;
R. sub. 4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R. sub. 4 together with R. sub. 5 can represent --CH. sub. 2 --O--;
X is a valency bond, --CH. sub. 2, oxygen or sulfur;
Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;
R. sub. 5 and R. sub. 6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH. sub. 2 -- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or
R. sub. 5 and R. sub.
Use Of, And Method Of Treatment Using, Carbazolyl-(4)-Oxypropanolamine Compounds For Inhibition Of Smooth Muscle Cell Proliferation
US Patent:
5308862, May 3, 1994
Filed:
Mar 5, 1993
Appl. No.:
8/026892
Inventors:
Eliot H. Ohlstein - Glenmoore PA
Assignee:
Boehringer Mannheim Pharmaceuticals Corporation - SmithKline Beecham
Corp., Ltd. Partnership No. 1 - Rockville MD
Corp., Ltd. Partnership No. 1 - Rockville MD
International Classification:
A61K 3140
US Classification:
514411
Abstract:
A new use of, and method of treatment using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R. sub. 1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;
R. sub. 2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;
R. sub. 3 is hydrogen or lower alkyl of up to 6 carbon atoms;
R. sub. 4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R. sub. 4 together with R. sub. 5 can represent --CH. sub. 2 --O--;
X is a valency bond, --CH. sub. 2, oxygen or sulfur;
Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;
R. sub. 5 and R. sub. 6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH. sub. 2 -- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or
R. sub. 5 and R. sub.
Use Of Factor Xiiia Inhibitors To Treat Atherosclerosis
US Patent:
2004010, Jun 3, 2004
Filed:
Nov 25, 2003
Appl. No.:
10/722081
Inventors:
Anne Arnold - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Eliot Ohlstein - Glenmoore PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
A61K039/395, G01N033/53
US Classification:
424/145100, 435/007100
Abstract:
A method of treating a mammal, preferably a human, having atherosclerotic disease is provided. The method comprises administering to the mammal an inhibitor of Factor XIIIa which is involved in the formation of atherosclerotic lesions. Methods for identifying Factor XIIIa inhibitors are also provided.
Pharmaceutical Combinations Of Beta-3 Adrenergic Receptor Agonists And Muscarinic Receptor Antagonists
US Patent:
8642661, Feb 4, 2014
Filed:
Aug 2, 2011
Appl. No.:
13/196068
Inventors:
Stephen Caltabiano - King of Prussia PA, US
Eliot Ohlstein - Glenmoore PA, US
Stewart McCallum - King of Prussia PA, US
Eliot Ohlstein - Glenmoore PA, US
Stewart McCallum - King of Prussia PA, US
Assignee:
Altherx, Inc. - Glenmoore PA
International Classification:
A01N 33/02, A61K 31/135, A01N 33/00, A61K 31/13, A61K 31/16, A01N 43/04, A61K 31/70
US Classification:
514646, 514579, 514 25, 514659
Abstract:
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
Pharmaceutical Combination
US Patent:
2013017, Jul 4, 2013
Filed:
Feb 8, 2013
Appl. No.:
13/762563
Inventors:
Eliot Ohlstein - Glenmoore PA, US
Stewart Mccallum - King Of Prussia PA, US
Stewart Mccallum - King Of Prussia PA, US
Assignee:
ALTHERX, INC. - Glenmoore PA
International Classification:
A61K 31/216, A61K 31/196, A61K 31/426, A61K 31/7024
US Classification:
514 23, 514534, 514370
Abstract:
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.